Home Cart Sign in  
Chemical Structure| 87-44-5 Chemical Structure| 87-44-5

Structure of β-Caryophyllene
CAS No.: 87-44-5

Chemical Structure| 87-44-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

β-Caryophyllene is an agonist of the cannabinoid (CB) receptor CB2 with Ki of 155 nM.

Synonyms: (-)-(E)-Caryophyllene; E-Caryophyllene; CCRIS 8094

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of β-Caryophyllene

CAS No. :87-44-5
Formula : C15H24
M.W : 204.35
SMILES Code : C=C1CC/C=C(C)/CC[C@@]2([H])C(C)(C)C[C@]12[H]
Synonyms :
(-)-(E)-Caryophyllene; E-Caryophyllene; CCRIS 8094
MDL No. :MFCD00075925

Safety of β-Caryophyllene

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H413
Precautionary Statements:P264-P270-P273-P301+P312-P330

Related Pathways of β-Caryophyllene

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 50 nM to 50 µM 24 hours To study the effect of BCP on steatosis induction, results showed that BCP significantly reduced intracellular triglyceride accumulation at concentrations ranging from 500 nM to 10 μM, with the maximum effect at 5 μM (22% reduction). Int J Mol Sci. 2023 Mar 23;24(7):6060
HaCaT keratinocytes 0.1 and 0.2 μg/mL 30 min pretreatment followed by 12 hours (mRNA) or 24 hours (protein) To evaluate the inhibitory effect of BCP on IL-4-induced TSLP expression. Results showed that BCP dose-dependently inhibited IL-4-induced TSLP mRNA and protein expression. Int J Mol Sci. 2022 Nov 28;23(23):14861
Peripheral blood monocytes 0.1 -100 nM 30 minutes To evaluate the effects of BCP-DHA combination on cytokine production in an MRSA infection model. Results showed significant reduction in GM-CSF, TNFα, IL-1, IL-6, and IL-12 levels and an increase in IL-10 levels in the BCP-DHA treatment groups. Sci Rep. 2022 Nov 10;12(1):19199
Beas 100 µM 48 hours Assess the toxicity of β-Caryophyllene on normal lung cells Beas, showing no significant toxicity at 100 μM Molecules. 2022 Nov 30;27(23):8354
A549 75 µM 48 hours Evaluate the effect of β-Caryophyllene on A549 cell proliferation, showing significant inhibition at 75 μM Molecules. 2022 Nov 30;27(23):8354
Bone marrow-derived macrophages (BMDMs) 20 µM 6 hours Inhibited RSL3-induced macrophage ferroptosis and reduced lipid peroxidation Int J Mol Sci. 2022 Dec 16;23(24):16055
RAW264.7 macrophages 20 µM 6 hours Inhibited RSL3-induced macrophage ferroptosis and reduced lipid peroxidation Int J Mol Sci. 2022 Dec 16;23(24):16055

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice DNCB-induced AD-like skin inflammation model Topical application 0.001, 0.1, and 100 μg/mL Once daily for 20 days To evaluate the therapeutic effect of BCP on AD-like skin inflammation. Results showed that BCP significantly alleviated DNCB-induced epidermal hyperplasia and inflammatory cell infiltration, and reduced EGR1 and TSLP expression. Int J Mol Sci. 2022 Nov 28;23(23):14861
Female BALB/c mice Urinary tract infection model Intraperitoneal injection 100 mg/kg Administered at 6 hours post-infection, evaluated at 24 or 72 hours To evaluate the antibacterial and analgesic effects of β-caryophyllene in a UTI model. Results showed significant reduction in bacterial burden in urine and bladder tissues, and improvements in behavioral responses and bladder inflammation parameters. Molecules. 2023 May 17;28(10):4144
Mice Permanent ischemia model (photothrombosis model) Intraperitoneal injection 3-30 mg/kg 1 hour before and 24 hours after To evaluate the effects of β-caryophyllene on infarct size, microglial activation, and motor performance. Results showed that 30 mg/kg of β-caryophyllene significantly reduced infarct size but did not significantly alter microglial number or immunofluorescence. Int J Mol Sci. 2021 Mar 11;22(6):2866
C57BL/6J mice DSS-induced ulcerative colitis model Oral 50 mg/kg Once daily for 7 days Inhibited macrophage ferroptosis by activating CB2R and alleviated colonic inflammation Int J Mol Sci. 2022 Dec 16;23(24):16055
Balb-C mice Acetic acid-induced abdominal writhing, formalin-induced paw edema, and von Frey mechanical hypernociception models Subcutaneous injection BCP (5 mg/kg), BCP + DHA (2.5 mg/kg each) Single dose 24 hours before the test To evaluate the anti-inflammatory and antinociceptive effects of BCP and DHA alone or in combination. Results showed significant reduction in acetic acid-induced abdominal writhing, formalin-induced paw edema, and von Frey mechanical hypernociception. Sci Rep. 2022 Nov 10;12(1):19199
Rats and mice Nicotine self-administration model Intraperitoneal injection 3, 10, 25, 50, and 100 mg/kg Single administration, 30 min prior Systemic administration of BCP dose-dependently inhibited nicotine self-administration and motivation for nicotine seeking in rats and mice. The reduction in nicotine self-administration by low-dose BCP (25 mg/kg) was blocked by the selective CB2 receptor antagonist AM630 but not by the selective CB1 receptor antagonist AM251, suggesting CB2 receptor mechanism involvement. Genetic deletion of CB2 receptors in mice blocked the reduction in nicotine self-administration only at low doses of BCP (25 mg/kg), but not at high doses (50 mg/kg), suggesting involvement of both CB2 and non-CB2 receptor mechanisms. Br J Pharmacol. 2020 May;177(9):2058-2072

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.89mL

0.98mL

0.49mL

24.47mL

4.89mL

2.45mL

48.94mL

9.79mL

4.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories